Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 1.00 |
| ▸ | CA2 | P00918 | 11/20 | 1.00 |
| ▸ | CA9 | Q16790 | 11/20 | 1.00 |
| ▸ | CA12 | O43570 | 10/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.60 |
| ▸ | CA6 | P23280 | 2/20 | 0.58 |
| ▸ | CA5A | P35218 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11245352 | 0.90 | CA12 (0.81) | CA1CA2CA9CA12CYP3A4 | |
| SCHEMBL4085333 | 0.89 | CA12 (0.80) | CA1CA2CA9CA12CYP3A4 | |
| SCHEMBL1082403 | 0.87 | CA12 (0.77) | CA1CA2CA9CA12CYP3A4 | |
| SCHEMBL27843904 | 0.86 | CA12 (0.75) | CA1CA2CA9CA12CYP3A4 | |
| SCHEMBL27661888 | 0.86 | CA12 (0.75) | CA1CA2CA9CA12CYP3A4 | |
| SCHEMBL8761233 | 0.86 | CA12 (0.75) | CA1CA2CA9CA12CYP3A4 | |
| SCHEMBL27681903 | 0.86 | CA12 (0.75) | CA1CA2CA9CA12CYP3A4 | |
| SCHEMBL923761 | 0.84 | CA1 (0.72) | CA1CA2CA9CA12CYP3A4 | |
| SCHEMBL10833147 | 0.83 | CA1 (0.71) | CA1CA2CA9CA12CYP3A4 | |
| SCHEMBL634316 | 0.82 | ALDH1A1 (0.71) | CA1CA2CA9CA12CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719413-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | Animol Discovery, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092070-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | ANIMOL DISCOVERY INC (US) | 2026-04-02 | — | — | US | disclosed |
| WO-2024246837-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | ANIMOL DISCOVERY, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20220315548-A1 | SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | 2022-10-06 | — | — | US | disclosed |
| WO-2021041866-A1 | SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| EP-1928879-B1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
| WO-2010061185-A2 | THERAPEUTIC TARGET | UNION LIFE SCIENCES LTD (GB) | 2010-06-03 | — | — | WO | disclosed |
| WO-2007038314-A2 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-06-10 | — | — | US | disclosed |
| EP-1353922-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | Cancer Research Technology Limited (GB) | 2003-10-22 | — | — | EP | disclosed |
| EP-1214318-B1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-08 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| WO-2002059125-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
| US-5342730-A | With mordant and stripping layers | EASTMAN KODAK COMPANY (US) | 1994-08-30 | — | — | US | disclosed |
| US-4065559-A | FUNGICIDES | ELI LILLY AND COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315548-A1 | SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF | MCOLN1, MCOLN2, MCOLN3 | CA1 4224/4885CA2 2953/4885CA9 4035/4885 |
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | CA1 3416/4885CA2 4522/4885CA9 4511/4885 |
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP2K2, MAP3K2, MAP4K2 | CA1 4207/4885CA2 2561/4885CA9 4477/4885 |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CCNA1, CDKL1, CCNK | CA1 2976/4885CA2 2384/4885CA9 2902/4885 |
| US-20260092070-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | JAK1, JAK3, JAK2 | CA1 2926/4885CA2 1072/4885CA9 3140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.